Levodopa/Benserazide

Dopamine Precursor·Neurology - Anti-Parkinson & Cognitive

Parkinson's disease (PD)

Authority requiredPBSANTI-PARKINSONMadopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)S4+1

Max Dose

1000+ mg/day

Half-life

1.5 h

Withdrawal

NMS RISK

Dyskinesia

CHRONIC RISK

Rapid Summary

Overview

The gold-standard dopamine replacement therapy for Parkinson's Disease. Levodopa crosses the BBB, while Benserazide stops it from breaking down in the body, preventing severe nausea.

Maximum Dose

Titrated strictly to effect. Standard max is ~1000 mg/day of Levodopa component.

Clinical Focus

Doses MUST be given exactly on time (e.g., 0800, 1200, 1600). A 30-minute delay leaves the patient frozen and unable to move or swallow.

Bottom Line

Levodopa/Benserazide is the most effective treatment for Parkinson's motor symptoms, but long-term use inevitably causes motor fluctuations (wearing-off, dyskinesias) requiring careful dose timing.

Formulation & Access

Brand Names

Madopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)

Oral Routes

Capsules/Tablets (50/12.5 mg, 100/25 mg, 200/50 mg). Dispersible tablets (Madopar Rapid). Controlled Release (HBS).

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Parkinson's disease (PD).

Clinical Place

The most effective drug for treating the bradykinesia and rigidity of PD.

Quick reference

Class & Role

Dopamine Precursor — The gold-standard dopamine replacement therapy for Parkinson's Disease.

Route / Formulation

Capsules/Tablets (50/12.5 mg, 100/25 mg, 200/50 mg). Dispersible tablets (Madopar Rapid). Controlled Release (HBS). (Madopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa))

Usual Dose & Max

Start PO 50/12.5 mg BD or TDS. Gradually titrate up over weeks. Maintenance often 100/25 mg TDS to QID. Titrated strictly to effect. Standard max is ~1000 mg/day of Levodopa component.

Key Indication Doses

Parkinson's Disease: Start PO 50/12.5 mg BD or TDS. Gradually titrate up over weeks. Maintenance often 100/25 mg TDS to QID. Restless Legs Syndrome: PO 50/12.5 mg NOCTE (Off-label). Timing: Take 30-60 mins BEFORE meals to avoid protein blocking absorption.

Best Uses

Levodopa/Benserazide is the most effective treatment for Parkinson's motor symptoms, but long-term use inevitably causes motor fluctuations (wearing-off, dyskinesias) requiring careful dose timing.

Avoid / Cautions

Concurrent use of non-selective MAOIs, narrow-angle glaucoma.

Key Risks

Neurological: Parkinsonism-Hyperpyrexia Syndrome (similar to NMS) if abruptly withdrawn. HIGH — Dyskinesias (writhing, chorea-like movements) with chronic use. 'On-Off' fluctuations. Psychiatric: Visual hallucinations, psychosis, severe impulse control disorders (gambling/hypersexuality), confusion. Cardiovascular: Orthostatic hypotension, syncope. Gastrointestinal: Nausea/Vomiting (mitigated by the benserazide).

Key Interactions

Antipsychotics (Haloperidol, Metoclopramide) are D2 antagonists. They directly block Levodopa from working, instantly paralyzing the Parkinson's patient. If an antiemetic is needed, use Domperidone or Ondansetron. If an antipsychotic is needed, use Quetiapine.

Monitoring

Strict adherence to medication timings. Monitor for orthostatic BP drops and hallucinations. No specific routine laboratory tests required.

Clinical Pearl

Amino acids from dietary protein compete with Levodopa for the exact same transporter across the gut wall and the blood-brain barrier. If taken with a steak dinner, absorption drops to near zero. Must be taken on an empty stomach.

Access

Authority requiredMadopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)

Brand: Madopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)
PBS status: Authority required
Formulation: Capsules/Tablets (50/12

Levodopa/Benserazide

Dopamine Precursor·Neurology - Anti-Parkinson & Cognitive

Parkinson's disease (PD)

Authority requiredPBSANTI-PARKINSONMadopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)S4+1

Max Dose

1000+ mg/day

Half-life

1.5 h

Withdrawal

NMS RISK

Dyskinesia

CHRONIC RISK

Rapid Summary

Overview

The gold-standard dopamine replacement therapy for Parkinson's Disease. Levodopa crosses the BBB, while Benserazide stops it from breaking down in the body, preventing severe nausea.

Maximum Dose

Titrated strictly to effect. Standard max is ~1000 mg/day of Levodopa component.

Clinical Focus

Doses MUST be given exactly on time (e.g., 0800, 1200, 1600). A 30-minute delay leaves the patient frozen and unable to move or swallow.

Bottom Line

Levodopa/Benserazide is the most effective treatment for Parkinson's motor symptoms, but long-term use inevitably causes motor fluctuations (wearing-off, dyskinesias) requiring careful dose timing.

Formulation & Access

Brand Names

Madopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)

Oral Routes

Capsules/Tablets (50/12.5 mg, 100/25 mg, 200/50 mg). Dispersible tablets (Madopar Rapid). Controlled Release (HBS).

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Parkinson's disease (PD).

Clinical Place

The most effective drug for treating the bradykinesia and rigidity of PD.

Quick reference

Class & Role

Dopamine Precursor — The gold-standard dopamine replacement therapy for Parkinson's Disease.

Route / Formulation

Capsules/Tablets (50/12.5 mg, 100/25 mg, 200/50 mg). Dispersible tablets (Madopar Rapid). Controlled Release (HBS). (Madopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa))

Usual Dose & Max

Start PO 50/12.5 mg BD or TDS. Gradually titrate up over weeks. Maintenance often 100/25 mg TDS to QID. Titrated strictly to effect. Standard max is ~1000 mg/day of Levodopa component.

Key Indication Doses

Best Uses

Levodopa/Benserazide is the most effective treatment for Parkinson's motor symptoms, but long-term use inevitably causes motor fluctuations (wearing-off, dyskinesias) requiring careful dose timing.

Avoid / Cautions

Concurrent use of non-selective MAOIs, narrow-angle glaucoma.

Key Risks

Key Interactions

Monitoring

Strict adherence to medication timings. Monitor for orthostatic BP drops and hallucinations. No specific routine laboratory tests required.

Clinical Pearl

Access

Authority requiredMadopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)

Brand: Madopar (Levodopa/Benserazide), Sinemet (Levodopa/Carbidopa)
PBS status: Authority required
Formulation: Capsules/Tablets (50/12